Results 91 to 100 of about 11,407 (210)

A prospective one-year microbiologic survey of combined pneumonia and respiratory failure [PDF]

, 2017
Background: Pneumonia and respiratory failure are common problems in the intensive care unit (ICU) setting, often occurring together. The relative prevalence of pneumonia types (community acquired, hospital acquired, ventilator associated) and causative ...
Fisher, Kristen, Juang, Paul, Kollef, Marin H, Micek, Scott T, Trupka, Tracy   +4 more
core   +2 more sources

The Evaluation of Machine Learning Models Using Matrix‐Assisted Laser Desorption/Ionization Time‐of‐Flight Mass Spectrometry (MALDI–TOF–MS) Spectra for the Prediction of Antibiotic Resistance in Klebsiella pneumoniae

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
Machine learning models developed from matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry spectra can rapidly predict antimicrobial resistance in Klebsiella pneumoniae. By transforming routine spectral data into accurate resistance profiles within minutes, this approach could reduce diagnostic delays and support earlier ...
Stephen Mark Edward Fordham
wiley   +1 more source

Bacteriophage Therapy: Current Strategies and Future Perspectives

MedComm, Volume 7, Issue 3, March 2026.
This manuscript systematically reviews the expanding scope of phage applications. It moves beyond traditional antibacterial use to explore their role in precision therapies against drug‐resistant infections, their synergy with antibiotics, and advanced biomaterial‐assisted delivery systems.
Zihe Zhou, Hanyu Fu, Mengzhe Li, Zhongyu Han, Zhenchao Wu, Huahao Fan, Ning Shen, Jiajia Zheng   +7 more
wiley   +1 more source

Carbapenemase-producing organisms: a global scourge [PDF]

, 2018
The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern.
Bonomo, Robert A, Burd, Eileen M, Conly, John, Limbago, Brandi M, Poirel, Laurent, Segre, Julie A, Westblade, Lars F   +6 more
core  

Necrotising Soft Tissue Infections: A Single Center's Case Series

International Wound Journal, Volume 23, Issue 3, March 2026.
ABSTRACT Necrotising soft tissue infection (NSTI) is a progressive disease with a time‐dependent prognosis; if not promptly treated, it can lead to significant morbidity as well as mortality. Early and aggressive surgical treatment is mandatory for appropriate management. This study reports the diagnostic and therapeutic pathway, surgical treatment and
Francesca Toia, Andrea Pio Cascino, Mara Franza, Marco Romeo, Antonino Speciale, Adriana Cordova, Massimiliano Tripoli   +6 more
wiley   +1 more source

Cyclic Boronates Inhibit All Classes of β-Lactamase [PDF]

, 2017
β-Lactamase-mediated resistance is a growing threat to the continued use of β-lactam antibiotics. The use of the β-lactam-based serine-β-lactamase (SBL) inhibitors clavulanic acid, sulbactam, tazobactam, and, more recently, the non-β-lactam inhibitor ...
Brem, J, Cahill, ST, Cain, R, Fishwick, CWG, Lohans, CT, McDonough, MA, Mohammed, J, Oswin, HP, Schofield, CJ, Spencer, J, Wang, DY, Wareham, DW   +11 more
core   +5 more sources

Role of cephalosporins in the era of Clostridium difficile infection [PDF]

, 2016
The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-analyses have suggested a strong association between cephalosporin use and CDI, and many national programmes on CDI control have focused on ...
Brogard, Carl E. Nord, Edlund, Emilio Bouza, Griffith, James D. Chalmers, Jane Freeman, Kalman, Marino, Mark H. Wilcox, Moorthi, Novelli, Tanimura   +12 more
core   +2 more sources

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
ABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Jingjing Wang, Jinjie He, Jufang Wu, Jing Zhang, Ying Ma, Xiaoqing Ren, Hua Wei, Chunye Zhang, Hua Zhu, Susan R. Raber, Shuangchen Cong   +10 more
wiley   +1 more source

Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health" Approach. [PDF]

, 2019
Treating infection is a key part of the work of most clinicians [...]
Lipman, J, Lonsdale, DO
core   +1 more source